Drug Profile
Research programme: autoimmune disorders/cancer - Genentech/Xencor
Alternative Names: CD20 XmAb™; Her2 XmAb™Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genentech; Xencor
- Class Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 10 Mar 2008 This collaboration is still active